Business Context and Reporting Period
vTv Therapeutics Inc. (NASDAQ: VTVT) is a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory diseases. The company's lead program is cadisegliatin, a glucokinase activator for Type 1 diabetes. This Form 10-Q covers the quarterly period ended September 30, 2024.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1,000 | $0 |
| Net Loss (Attributable to vTv) | $(4,783) | $(6,654) | $(14,828) | $(16,772) |
| Net Loss Per Share (Basic/Diluted) | $(0.88) | $(3.19) | $(2.70) | $(8.04) |
| Cash and Cash Equivalents (End of Period) | $41,571 (as of Sept 30, 2024) | |||
| Net Cash Used in Operating Activities | N/A (Quarterly) | $(20,482) | $(16,167) | |
| Net Cash Provided by Financing Activities | N/A (Quarterly) | $52,607 | $12,279 | |
| Accumulated Deficit | $(296,084) (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $9.4 million at year-end 2023 to $41.6 million at September 30, 2024. This was driven by a $51.0 million private placement in February 2024 and $2.5 million in ATM offering proceeds.
- Revenue Recognition: The company recognized $1.0 million in revenue for the nine months ended September 30, 2024, resulting from a development milestone under the Newsoara License Agreement. No revenue was recognized in the comparable 2023 period.
- Operating Expenses:
- R&D: Decreased by $2.1 million (18.7%) for the nine months ended Sept 30, 2024, primarily due to lower spending on the cadisegliatin program (reduced toxicity and manufacturing costs) offset by increased indirect costs.
- G&A: Increased by $1.6 million (17.5%) for the nine months ended Sept 30, 2024, driven by higher payroll, legal, and share-based compensation expenses.
- Other Income/Expense: Net other income improved significantly in 2024 compared to 2023, which included a $4.2 million impairment charge on an investment in Anteris Bio, Inc. in the prior year.
Outlook, Risks, and Management Commentary
- Clinical Hold: On July 26, 2024, the FDA issued a clinical hold on the cadisegliatin program, including the CATT1 trial, due to an unresolved chromatographic signal in an ADME study. The company must complete a single in vitro study to characterize the signal before trials can resume. No patients had been dosed in the CATT1 trial at the time of the hold.
- Liquidity Outlook: Management believes current cash resources ($41.6 million) are sufficient to meet liquidity requirements for at least the next twelve months. The company is evaluating additional financing strategies, including equity offerings and potential partnerships.
- Partnership Updates:
- G42: The company continues to work with G42 to initiate a Phase 2 trial for Type 2 diabetes in the Middle East, expected to begin in 2025.
- OnKure: On October 22, 2024, OnKure notified the company of its intent to terminate the license agreement for the PPAR-delta agonist program, effective January 20, 2025, citing a decision to discontinue development.
- Capital Structure: The company has an ATM facility with TD Cowen for up to $50.0 million, with $47.5 million remaining available as of September 30, 2024.
Key Facts for Investor Verification
- Regulatory Status: Verify the timeline and requirements for lifting the FDA clinical hold on cadisegliatin and the potential impact on the 2026 start date for registrational studies.
- Cash Burn Rate: Monitor the net cash used in operating activities ($20.5 million for 9 months) against the current cash balance ($41.6 million) to assess runway duration.
- Revenue Dependencies: Confirm the status of the $20.0 million upfront fee contingent on the Second Newsoara Amendment, which is due within one year of the June 2024 amendment.
- Related Party Transactions: Review the governance changes regarding MacAndrews & Forbes (M&F) and the reclassification of noncontrolling interest to permanent equity.
- Portfolio Reduction: Assess the financial impact of the OnKure termination on the company's pipeline and future royalty potential.